Navigation Links
Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine
Date:5/8/2008

ts. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from those expected, including Vion's potential inability to obtain regulatory approval for its products, particularly Cloretazine(R) (VNP40101M), delayed or unfavorable results of drug trials, the possibility that favorable results of earlier preclinical studies or clinical trials are not predictive of safety and efficacy results in later clinical trials, the need for additional research and testing, the inability to manufacture product, the potential inability to secure external sources of funding to continue operations, the inability to access capital and funding on favorable terms, continued operating losses and the inability to continue operations as a result, and a variety of other risks set forth from time to time in Vion's filings with the Securities and Exchange Commission, including but not limited to the risks attendant to the forward-looking statements included under Item 1A, "Risk Factors" in Vion's Form 10-K for the year ended December 31, 2007. In particular, there can be no assurance as to the results of any of the Vion's clinical trials, that any of these trials will continue to full accrual, or that any of these trials will not be discontinued, modified, delayed or ceased altogether. Except in special circumstances in which a duty to update arises under law when prior disclosure becomes materially misleading in light of subsequent events, Vion does not intend to update any of these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

COMPANY CONTACT: Vion Pharmaceuticals, Inc.

Alan Kessman, Chief Executive Officer

Howard B. Johnson, President & CFO

(203) 498-4210


'/>"/>
SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
2. Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer
3. Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
4. Alseres Pharmaceuticals Enters Agreement to Amend Cethrin(R) License to Lower Milestone Payments and Royalty Rates
5. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
6. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
7. Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals Nicotinic Alpha-7 Agonist, MEM 3454
8. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
9. ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing
10. Cequent Pharmaceuticals Johannes Fruehauf, MD, Ph.D., to be Featured Speaker at RNAi World Congress in Boston - May 2, 2008
11. Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 19, 2014 The Parenteral Drug Association (PDA) ... post-approval changes protocols. The new initiative ... expressed by industry participants and regulatory authority representatives at ... in Washington, DC . Representatives of ... for the workshop. Attendees indicated openness to engaging regulators ...
(Date:9/19/2014)... DALLAS , Sept. 19, 2014 ... Market Outlook to 2020″, provides key ... General Surgery devices market. The report ... dollars, and volume (in units) within ... Cystoscopes, Colonoscopes, Sigmoidoscopes, Esophagoscopes & Gastroscopes, ...
(Date:9/19/2014)...  The board of directors of AbbVie Inc. (NYSE: ... of $0.42 per share.  The cash ... record at the close of business on Oct. 15, ... research-based biopharmaceutical company formed in 2013 following separation from ... dedicated people and unique approach to innovation to develop ...
Breaking Medicine Technology:PDA Launches Effort to Harmonize Global Post-Approval Changes Protocols 2United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 2United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 3United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 4United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 5
... BRUNSWICK, N.J., Dec. 15, 2010 Johnson & Johnson ... Gorsky, currently Worldwide Chairman, Medical Devices & Diagnostics (MD&D) ... appointed Vice Chairmen of the Executive Committee and join ... Executive Officer, in an expanded Office of the Chairman. ...
... Control Risks , one of the world,s leading ... its annual review and forecast of business risk for the ... and security risk in 173 countries. 2011 will ... both politically and economically, as the world,s emerging economies use ...
Cached Medicine Technology:Johnson & Johnson Announces Executive Appointments: Alex Gorsky, Vice Chairman, Executive Committee Sheri McCoy, Vice Chairman, Executive Committee 2Johnson & Johnson Announces Executive Appointments: Alex Gorsky, Vice Chairman, Executive Committee Sheri McCoy, Vice Chairman, Executive Committee 3Control Risks Forecasts New Reality for Business in 2011 Brought by Emerging Markets, Legislation 2
(Date:9/20/2014)... -- As flu season approaches, the best way to ... flu shot and a checkup, according to an infectious ... vaccinate people against the flu, and also address other ... may provide flu shots for their customers, but they ... medical director of infection prevention and control for the ...
(Date:9/20/2014)... 2014 As concerns surrounding the ... in gynecological surgeries continue to grow, Bernstein Liebhard ... plans to end coverage for uterine morcellation. According ... month, Harrisburg, Pennsylvania-based Capital BlueCross will end coverage ... insurer said its decision was prompted by concerns ...
(Date:9/20/2014)... Traditionally dentists have advised their patients against drinking ... is re-visiting that advice and changing his stance after ... wine have on oral health. “There’s good news and great ... be beneficial in protecting against gum disease, and red wine ... coffee was from the September 2014 issue of Boston ...
(Date:9/20/2014)... 20, 2014 Earlier this week, Home Depot ... have had their credit card information pilfered by hackers, surpassing ... slew of headline articles like this one published ... eye opening numbers. , “Most people tend to focus ... it’s a way to score a game,” says Joe Caruso, ...
(Date:9/20/2014)... 2014 The Arizona Advanced Manufacturing ... celebrating National Manufacturing Day by opening its doors to ... and additive manufacturing labs will be offered between 10 ... MCC’s Southern and Dobson campus (1833 W. Southern Ave, ... D. , The AzAMI at MCC was established in ...
Breaking Medicine News(10 mins):Health News:Get a Flu Shot During Checkup, Doctor Says 2Health News:As Power Morcellator Concerns Grow, Bernstein Liebhard LLP Notes Another Insurer’s Decision to Drop Coverage for Uterine Morcellation 2Health News:As Power Morcellator Concerns Grow, Bernstein Liebhard LLP Notes Another Insurer’s Decision to Drop Coverage for Uterine Morcellation 3Health News:South Charlotte Dentist, Dr. James Wells, is Changing His Advice on Coffee and Wine Drinking 2Health News:South Charlotte Dentist, Dr. James Wells, is Changing His Advice on Coffee and Wine Drinking 3Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 2Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 3Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 4Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 5Health News:National Manufacturing Day Open House at Mesa Community College Oct. 3 2
... 23 WebMD Health Corp. (Nasdaq: WBMD ) ... that executives of WebMD are scheduled to participate at the ... 25, 2009 at 12:40 p.m. ET. Investors, analysts and ... audio broadcast of the presentation over the Internet. The ...
... On Wednesday, February 25, 2009, the Institute for ... roundtable discussion bringing leading scientists in the field of ... significance (MGUS). The event is being cochaired by James ... at the IMBCR and Robert A. Kyle, MD, who ...
... with Crain,s Cleveland Business, today presented a 2009 NorTech ... development of a Biotech Platform to Detect, Monitor, and ... developed a set of diagnostic tests used by physicians ... by determining drug resistance and disease "strength" of the ...
... #1 FOR IMMEDIATE RELEASE , Egg-irony: High cholesterol food ... Chemistry , Researchers in Canada are reporting evidence that ... may reduce another heart disease risk factor high ... that act like a popular group of prescription medications in ...
... TAMPA, Fla., Feb. 23 /PRNewswire/ -- ... data management solutions company, today announced the release ... cleanses, standardizes and integrates data from multiple platforms. ... businesses encompassing small, mid-size and "Fortune 500" companies, ...
... Sunrise Senior Living, Inc. (NYSE: SRZ ) today ... on Monday, March 2, 2009, at 9 a.m. ET to ... Mark Ordan, chief executive officer, and Richard Nadeau, chief financial ... conference call is 877-795-3638 or 719-325-4841 (from outside the U.S.). ...
Cached Medicine News:Health News:International Panel of Experts Gather for Roundtable Consensus Regarding Multiple Myeloma Related Disease 2Health News:Case Western Reserve University faculty named 2009 NorTech Innovation Award winner 2Health News:American Chemical Society's Weekly PessPac -- Feb. 18, 2009 2Health News:American Chemical Society's Weekly PessPac -- Feb. 18, 2009 3Health News:American Chemical Society's Weekly PessPac -- Feb. 18, 2009 4Health News:American Chemical Society's Weekly PessPac -- Feb. 18, 2009 5Health News:American Chemical Society's Weekly PessPac -- Feb. 18, 2009 6Health News:American Chemical Society's Weekly PessPac -- Feb. 18, 2009 7Health News:American Chemical Society's Weekly PessPac -- Feb. 18, 2009 8Health News:Industry Leading Data Quality and Householding Software Receives New Functionality for Enhanced Performance and Speed 2Health News:Sunrise to Host Conference Call and Webcast to Discuss Fourth-Quarter and Full-Year 2008 Financial Results 2
... The Vibratome 1500 Sectioning System provides ... fixed, animal, or plant tissues. The ... allows sectioning without freezing or embedding. ... morphology, the destruction of enzyme activities, and ...
... System provides a versatile means of sectioning ... The 1000 employs a vibrating blade ... embedding. The creation of artifacts, the ... activities, and other deleterious effects inherent in ...
... System provides a versatile means of sectioning ... The 1500 employs a vibrating blade ... embedding. The creation of artifacts, the ... activities, and other deleterious effect inherent in ...
Instrument Cover for Vibratome....
Medicine Products: